Research ArticleImaging

Use of 99mTc-Tilmanocept as a Single Agent for Sentinel Lymph Node Identification in Breast Cancer: A Retrospective Pilot Study

Jonathan T. Unkart and Anne M. Wallace
Journal of Nuclear Medicine Technology September 2017, 45 (3) 181-184; DOI: https://doi.org/10.2967/jnmt.117.194415

Article Figures & Data

Tables

  • TABLE 1

    Patient Characteristics

    ParameterData
    Age (y)57.5 ± 7.4
    Body mass index (kg/m2)27.2 ± 3.3
    Injection protocol
     1-d4 (21.1%)
     2-d15 (78.9%)
    Surgery
     Lumpectomy16 (84.2%)
     Mastectomy3 (15.8%)
    T stage
     Tis1 (5.3%)
     T17 (36.8%)
     T28 (42.1%)
     T33 (15.8%)
    Estrogen receptor
     Positive17 (89.5%)
     Negative2 (10.5%)
    Progesterone receptor
     Positive17 (89.5%)
     Negative2 (10.5%)
    Her2 receptor
     Positive1 (5.3%)
     Negative18 (94.7%)
    Lymphoscintigraphy
     Performed17 (89.5%)
     Nodal uptake13 (76.5%)
     Not performed2 (10.5%)

    • Data are mean ± SD or number followed by percentage in parentheses (n = 19 patients).

  • TABLE 2

    Findings in the 3 Patients with Disease-Positive SLNs

    Pathologic findings on…
    PatientSLN biopsyAxillary node biopsy
    11 of 3 nodes0 of 15 nodes
    21 of 2 nodes0 of 19 nodes
    31 of 2 nodesNot applicable*

    • ↵* Axillary lymph node dissection not performed.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords